$宝济药业-B(02_老虎社区_美港股上老虎

$宝济药业-B(02659)$ 宝济自主研发的注射用KJ103新药上市许可申请（NDA）获国家药品监督管理局（NMPA）受理，并将其已纳入优先审评程序，拟用于高度致敏的肾移植患者的脱敏治疗。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":571615166210288,"tweetId":"571615166210288","gmtCreate":1780578664323,"gmtModify":1780579025360,"author":{"id":4218001298160580,"idStr":"4218001298160580","authorId":4218001298160580,"authorIdStr":"4218001298160580","name":"G股叶荣添","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 宝济自主研发的注射用KJ103新药上市许可申请（NDA）获国家药品监督管理局（NMPA）受理，并将其已纳入优先审评程序，拟用于高度致敏的肾移植患者的脱敏治疗。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 宝济自主研发的注射用KJ103新药上市许可申请（NDA）获国家药品监督管理局（NMPA）受理，并将其已纳入优先审评程序，拟用于高度致敏的肾移植患者的脱敏治疗。</p></body></html>","text":"$宝济药业-B(02659)$ 宝济自主研发的注射用KJ103新药上市许可申请（NDA）获国家药品监督管理局（NMPA）受理，并将其已纳入优先审评程序，拟用于高度致敏的肾移植患者的脱敏治疗。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/571615166210288","repostId":0,"isVote":1,"tweetType":1,"viewCount":34,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02659"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":158,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}